Abstract:Liver dysfunction is a common complication of Graves' disease (GD) that may be caused by excessive thyroid hormone (TH) or anti-thyroid drugs (ATDs). Radioactive iodine (RAI) therapy is one of the first-line treatments for GD, but it is unclear whether it is safe and effective in patients with liver dysfunction. 510 consecutive patients with GD receiving first RAI were enrolled in the study, and followed up at 3-, 6- and 12-month. Liver dysfunction was recorded in 222 (43.5%) patients. GD patients with liver dysfunction had higher serum levels of free triiodothyronine (FT3) (median 27.6 vs. 20.6 pmol/L, p < 0.001) and free thyroxine (FT4) (median 65.4 vs. 53.5 pmol/L, p < 0.001) levels than those with normal liver function. Binary logistic regression analysis showed that duration of disease (OR = 0.951, 95% CI: 0.992-0.980, p = 0.001) and male gender (OR = 1.106, 95% CI: 1.116-2.384; p = 0.011) were significant differential factors for liver dysfunction. Serum TSH levels were higher in patients with liver dysfunction at all 3 follow-up time points (p = 0.014, 0.008, and 0.025 respectively). FT3 level was lower in patients with liver dysfunction at 3-month follow-up (p = 0.047), but the difference disappeared at 6 and 12 months (p = 0.351 and 0.264 respectively). The rate of euthyroidism or hypothyroidism was higher in patients with liver dysfunction than in those with normal liver function at 3 months (74.5% vs 62.5%; p = 0.005) and 6 months (82.1% vs 69.1%; p = 0.002) after RAI treatment, but the difference did not persist at 12-month follow-up (89.6% vs 83.2%, p = 0.081).There were no statistically significant differences in treatment efficacy (94.48% vs 90.31%, p = 0.142), incidence of early-onset hypothyroidism (87.73% vs 83.67%, p = 0.277), and recurrence rate (4.91% vs 7.14%, p = 0.379) between the 2 groups at 12-month follow-up. In conclusion, the efficacy of RAI was comparable in GD patients with liver dysfunction and those with normal liver function.

Comparing the prognostic impact of 131I or/and artificial liver support system on liver function failure combined with hyperthyroidism

WITHDRAWN: Comparing the Prognostic Impact of 131I Or/and Artificial Liver Support System on Liver Function Failure Combined with Hyperthyroidism

Efficacy of different therapeutic modalities for patients with acute-on-chronic liver failure induced by hepatitis B

Predictive values of three indexes on short-term prognosis in patients with liver failure treated by artificial liver support system

Treatment of Hepatic Failure with Artificial Liver Support System.

Effect of Artificial Liver Support System on Patients with Severe Viral Hepatitis: A Study of Four Hundred Cases

Effect of Liver Dysfunction on Outcome of Radioactive Iodine Therapy for Graves' Disease.

COMBINATION OF MOLECULAR ADSORBENT RECIRCULATING SYSTEM AND RADIOIODINE FOR THE TREATMENT OF CONCURRENT HYPERTHYROIDISM AND SEVERE LIVER DYSFUNCTION: A RETROSPECTIVE COHORT STUDY.

Clinical Evaluation of Treatment with Artificial Liver Support System in Chronic Fulminant Viral Hepatitis

Severe Hepatitis Treated with an Artificial Liver Support System

A Clinical Study on the Treatment of Severe Hepatitis by a Combined Artificial Liver.

Clinical Analysis of 115 Cases of Hyperthyroidism Complicated with Liver Functional Damage

The impact of serum thyroid-stimulation hormone levels on the outcome of hepatitis B virus related acute-on-chronic liver failure: an observational study

A Single-Center Experience of Non-Bioartificial Liver Support Systems among Chinese Patients with Liver Failure

The curative effect of ALSS on 1-month mortality in AoCLF patients after 72 to 120 hours.

Effects of Artificial Liver Support System on Patients With Acute or Chronic Liver Failure

[Survival Analysis on Liver Failure Patients Treated with an Artificial Liver Support System].

Clinical features comparison of liver dysfunction induced by anti-thyroid drugs or hyperthyroidism

Clinical observation on the treatment of acute liver failure by combined non-biological artificial liver

Establishing a Metabolomic Model for the Prognosis of Hepatitis B Virus-Induced Acute-on-chronic Liver Failure Treated with Different Liver Support Systems

HINT: a novel prognostic model for patients with hepatitis B virus-related acute-on-chronic liver failure.